Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The World Health Organisation (WHO) released new guidelines recommending the use of injectable lenacapavir (LEN) twice a year ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of ...

Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...